BACKGROUND: VHR is a dual-specificity phosphatase, which dephosphorylates activated ERK1/2 and weakens the ERK signaling cascade in mammalian cells. A selective inhibitor is expected to be useful for revealing the physiological function of VHR. RESULTS: First, we investigated the molecular mechanism of VHR inhibition by a known natural product, RK-682. Kinetic analysis indicated that inhibition was competitive toward the substrate, and two molecules of RK-682 were required to inhibit one molecule of VHR. Based on the structure-activity relationships for VHR inhibition by RK-682 derivatives, we constructed a binding model using molecular dynamics calculation. Based on this model, we designed and synthesized a novel dimeric derivative. As expected, the dimeric derivative showed increased inhibition of VHR, supporting our proposed mechanism of VHR inhibition by RK-682. CONCLUSION: We have developed a novel inhibitor of VHR based on the results of kinetic analysis and docking simulation.
BACKGROUND:VHR is a dual-specificity phosphatase, which dephosphorylates activated ERK1/2 and weakens the ERK signaling cascade in mammalian cells. A selective inhibitor is expected to be useful for revealing the physiological function of VHR. RESULTS: First, we investigated the molecular mechanism of VHR inhibition by a known natural product, RK-682. Kinetic analysis indicated that inhibition was competitive toward the substrate, and two molecules of RK-682 were required to inhibit one molecule of VHR. Based on the structure-activity relationships for VHR inhibition by RK-682 derivatives, we constructed a binding model using molecular dynamics calculation. Based on this model, we designed and synthesized a novel dimeric derivative. As expected, the dimeric derivative showed increased inhibition of VHR, supporting our proposed mechanism of VHR inhibition by RK-682. CONCLUSION: We have developed a novel inhibitor of VHR based on the results of kinetic analysis and docking simulation.
Authors: Ekaterina V Bobkova; Wallace H Liu; Sharon Colayco; Justin Rascon; Stefan Vasile; Carlton Gasior; David A Critton; Xochella Chan; Russell Dahl; Ying Su; Eduard Sergienko; Thomas D Y Chung; Tomas Mustelin; Rebecca Page; Lutz Tautz Journal: ACS Med Chem Lett Date: 2011-02 Impact factor: 4.345
Authors: Lucia Musumeci; Marijke J Kuijpers; Karen Gilio; Alexandre Hego; Emilie Théâtre; Lisbeth Maurissen; Maud Vandereyken; Catia V Diogo; Christelle Lecut; William Guilmain; Ekaterina V Bobkova; Johannes A Eble; Russell Dahl; Pierre Drion; Justin Rascon; Yalda Mostofi; Hongbin Yuan; Eduard Sergienko; Thomas D Y Chung; Marc Thiry; Yotis Senis; Michel Moutschen; Tomas Mustelin; Patrizio Lancellotti; Johan W M Heemskerk; Lutz Tautz; Cécile Oury; Souad Rahmouni Journal: Circulation Date: 2014-12-17 Impact factor: 29.690
Authors: Jonathan A Panggabean; Sya'ban P Adiguna; Tutik Murniasih; Siti I Rahmawati; Asep Bayu; Masteria Y Putra Journal: Rev Bras Farmacogn Date: 2022-01-07 Impact factor: 2.464
Authors: Christopher J Caunt; Stephen P Armstrong; Caroline A Rivers; Michael R Norman; Craig A McArdle Journal: J Biol Chem Date: 2008-07-23 Impact factor: 5.157